Fund Holdings — Artia Global Partners LP

Total Portfolio Value:
$389.85M
Total Bought:
$37.29M
Total Sold:
$55.97M
Net Transaction:
-$18.68M
Notable People:
Onusa Nmn Chantanapongwanij, Artia Global Partners Gp Llc
Securities
▲▼
SharesValue
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Novo Nordisk A/SADR(NVO)691,743691,7430$88.82M$98.74M25.33%+$9.92M
Eli Lilly and Company(LLY)92,59392,5930$72.03M$83.83M21.50%+$11.80M
Merck & Co., Inc.(MRK)379,200442,504+63,304$50.04M$54.78M14.05%+$4.75M
Viking Therapeutics, Inc.(VKTX)433,580452,979+19,399$35.55M$24.01M6.16%-$11.54M
AstraZeneca PLCADR(AZN)190,752190,7520$12.92M$14.88M3.82%+$1.95M
Intra-Cellular Therapies Inc210,096216,519+6,423$14.54M$14.83M3.80%+$290.7K
Vertex Pharmaceuticals Incorporated(VRTX)28,90018,900-10,000$12.08M$8.86M2.27%-$3.22M
Alnylam Pharmaceuticals, Inc.(ALNY)035,000+35,000$0$8.51M2.18%+$8.51M
Axsome Therapeutics, Inc.(AXSM)87,84887,8480$7.01M$7.07M1.81%+$61.5K
argenx SEADR(ARGX)34,23815,138-19,100$13.48M$6.51M1.67%-$6.97M
Neurocrine Biosciences, Inc.(NBIX)45,00045,0000$6.21M$6.20M1.59%-$11.3K
Vaxcyte, Inc.(PCVX)76,25576,2550$5.21M$5.76M1.48%+$549.0K
Protagonist Therapeutics Inc124,440124,4400$3.60M$4.31M1.11%+$711.8K
Dyne Therapeutics, Inc.(DYN)119,488119,4880$3.39M$4.22M1.08%+$824.5K
Soleno Therapeutics Inc40,92494,424+53,500$1.75M$3.85M0.99%+$2.10M
Crinetics Pharmaceuticals In85,76585,7650$4.01M$3.84M0.99%-$173.2K
Insmed Incorporated(INSM)118,23653,436-64,800$3.21M$3.58M0.92%+$372.5K
Ocular Therapeutix, Inc.(OCUL)724,685500,000-224,685$6.59M$3.42M0.88%-$3.17M
Ionis Pharmaceuticals, Inc.(IONS)062,479+62,479$0$2.98M0.76%+$2.98M
Merus N V50,17150,1710$2.26M$2.97M0.76%+$709.4K
Celldex Therapeutics, Inc.(CLDX)075,300+75,300$0$2.79M0.71%+$2.79M
Apogee Therapeutics Inc61,59058,400-3,190$4.09M$2.30M0.59%-$1.79M
Springworks Therapeutics Inc53,93053,9300$2.65M$2.03M0.52%-$622.9K
IDEAYA Biosciences, Inc.(IDYA)52,49254,392+1,900$2.30M$1.91M0.49%-$393.6K
Verona Pharma PlcADS130,790130,7900$2.10M$1.89M0.49%-$213.2K
Xenon Pharmaceuticals Inc.(XENE)40,00040,0000$1.72M$1.56M0.40%-$162.4K
Mereo BioPharma Group plcADS(MREO)421,359421,3590$1.39M$1.52M0.39%+$126.4K
Charles River Laboratories International, Inc.(CRL)6,9056,9050$1.87M$1.43M0.37%-$444.5K
Kura Oncology, Inc.(KURA)39,47857,178+17,700$842.1K$1.18M0.30%+$335.2K
Newamsterdam Pharma Company
ORDINARY SHARES
54,28554,2850$1.28M$1.04M0.27%-$241.0K
Ascendis Pharma A/SADR(ASND)15,8947,440-8,454$2.40M$1.01M0.26%-$1.39M
Silence Therapeutics plcADS(SLN)52,47652,4760$1.13M$997.0K0.26%-$136.4K
Syndax Pharmaceuticals, Inc.(SNDX)048,263+48,263$0$990.8K0.25%+$990.8K
Keros Therapeutics, Inc.(KROS)020,000+20,000$0$914.0K0.23%+$914.0K
Corbus Pharmaceuticals Holdings, Inc.(CRBP)020,000+20,000$0$905.0K0.23%+$905.0K
EyePoint, Inc.(EYPT)51,500101,500+50,000$1.06M$883.0K0.23%-$181.5K
Annexon, Inc.(ANNX)147,485147,4850$1.06M$722.7K0.19%-$334.8K
Larimar Therapeutics, Inc.(LRMR)58,19090,490+32,300$441.7K$656.1K0.17%+$214.4K
Disc Medicine, Inc.(IRON)87,04013,440-73,600$5.42M$605.7K0.16%-$4.81M
Pliant Therapeutics, Inc.(PLRX)100,00050,000-50,000$1.49M$537.5K0.14%-$952.5K
Madrigal Pharmaceuticals, Inc.(MDGL)1,5571,5570$415.8K$436.2K0.11%+$20.4K
Sarepta Therapeutics, Inc.(SRPT)02,600+2,600$0$410.8K0.11%+$410.8K
AbbVie Inc.(ABBV)90,8210-90,821$16.54M$0—-$16.54M
Alpine Immune Sciences Inc51,7140-51,714$2.05M$0—-$2.05M
Arvinas, Inc.(ARVN)40,0000-40,000$1.65M$0—-$1.65M
Biomea Fusion, Inc.(BMEA)35,4520-35,452$530.0K$0—-$530.0K
Cytokinetics, Incorporated(CYTK)89,5250-89,525$6.28M$0—-$6.28M
Gritstone Bio Inc95,1700-95,170$244.6K$0—-$244.6K
Immunovant, Inc.(IMVT)21,3970-21,397$691.3K$0—-$691.3K
Janux Therapeutics, Inc.(JANX)47,9490-47,949$1.81M$0—-$1.81M
MacroGenics, Inc.(MGNX)64,0070-64,007$942.2K$0—-$942.2K
Poseida Therapeutics Inc86,0020-86,002$274.3K$0—-$274.3K
Rapt Therapeutics Inc137,3080-137,308$1.23M$0—-$1.23M
Vera Therapeutics, Inc.CL A(VERA)24,2980-24,298$1.05M$0—-$1.05M
Page 1 of 1
Artia Global Partners LP — 13F Holdings — Q2 2024 | TickerTrail